Comparing tumour heterogeneity in primary tumour, circulating tumour cells and metastases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON29203

Enrollment

Registered

2016-08-22

Start date

2016-10-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC niet kleincellig longcarcinoom, longkanker lungcancer, tumour heterogeneity, tumor heterogeniteit, CTC, circulating tumour cell, circulerende tumor cel

Interventions

Terminal patients are included after their informed consent and that of their families is received. We will withdraw some blood for analysis on CTCs. After the participants death, we will perform a wa

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with a histologically/cytologically proven pulmonary malignancy. 2. Patients have to have a non-curable disease state, without curative treatment options 3. Signed informed consent 4. Patients family has asserted their acceptance of the patients participation 5. Patients using anticoagulants such as fraxodi or acenocoumarol are allowed

Exclusion criteria

Exclusion criteria: 1. No growth factor medication

Design outcomes

Primary

Measure	Time frame
- heterogeneity and mutational load measurements in all compartments. These can subsequently be compared to one another.	—

Contacts

Public ContactH.J.M. Groen

UMCG Department of Pulmonary Disease, Box 30001

h.j.m.groen@int.umcg.nl+31 (0)50 3616161

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)